The trial accomplished each its Main endpoints, with semaglutide 2.4 mg demonstrating statistically major and superior advancements in liver fibrosis without having worsening of steatohepatitis, along with resolution of steatohepatitis without worsening of liver fibrosis in people with MASH when com